|
|
| Research article summary (published 13 Aug 2006): |
|
Free Full Text! See links below |
Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.
Full Abstract
Although crosstalk between cell-surface and nuclear receptor signaling pathways has been implicated in the development and progression of endocrine-regulated cancers, evidence of direct coupling of these signaling pathways has remained elusive. Here we show that estrogen promotes an association between extranuclear estrogen receptor alpha (ER) and the epidermal growth factor receptor (EGFR) family member ERBB4. Ectopically expressed as well as endogenous ERBB4 interacts with and potentiates ER transactivation, indicating that the ERBB4/ER interaction is functional. Estrogen induces nuclear translocation of the proteolytic processed ERBB4 intracellular domain (4ICD) and nuclear translocation of 4ICD requires functional ligand-bound ER. The nuclear ER/4ICD complex is selectively recruited to estrogen-inducible gene promoters such as progesterone receptor (PgR) and stromal cell-derived factor 1 (SDF-1) but not to trefoil factor 1 precursor (pS2). Consistent with 4ICD-selective promoter binding, suppression of ERBB4 expression by interfering RNA shows that 4ICD coactivates ER transcription at the PgR and SDF-1 but not the pS2 promoter. Significantly, ERBB4 itself is an estrogen-inducible gene and the ERBB4 promoter harbors a consensus estrogen response element (ERE) half-site with overlapping activator protein-1 elements that bind ER and 4ICD in response to estrogen. Using a cell proliferation assay and a small interfering RNA approach, we show that ERBB4 expression is required for the growth-promoting action of estrogen in the T47D breast cancer cell line. Our results indicate that ERBB4 is a unique coregulator of ER, directly coupling extranuclear and nuclear estrogen actions in breast cancer. We propose that the contribution of an autocrine ERBB4/ER signaling pathway to tumor growth and therapeutic response should be considered when managing patients with ER-positive breast cancer.
Learn Faster Today Improve your study skills
Author information
Author/s: Zhu, Yun (Y); Sullivan, Lacey L (LL); Nair, Sujit S (SS); Williams, Christopher C (CC); Pandey, Arvind K (AK); Marrero, Luis (L); Vadlamudi, Ratna K (RK); Jones, Frank E (FE);
Affiliation: Department of Biochemistry, Tulane University Health Sciences Center, Tulane Cancer Center, New Orleans, LA 70112-2699, USA.
Grants: R01CA95783 (Agency:NCI NIH HHS) ; R01CA96717 (Agency:NCI NIH HHS)
Journal and publication information
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal: Cancer research (Cancer Res), published in United States. (Language: eng)
Reference: 2006-Aug; vol 66 (issue 16) : pp 7991-8
Dates: Created 2006/08/16; Completed 2007/11/13; Revised 2007/12/03;
PMID: 16912174, status: MEDLINE (last retrieval date: 12/26/2008)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article (including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
|
|
Related articles
These are the highest related articles currently in the database:
- Evaluation of biological pathways involved in chemotherapy response in breast cancer.
27 Apr 2008 - Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
30 May 2008 - Different effects of PCB101, PCB118, PCB138 and PCB153 alone or mixed in MCF-7 breast cancer cells.
12 Apr 2008 - Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
27 Jul 2008 - Role of ErbB4 in breast cancer.
May 2008 - Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.
15 Jul 2008 - A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer.
20 Jul 2008 - A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate.
14 Sep 2008 - Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
29 Apr 2008 - Electromagnetic fields alter the expression of estrogen receptor cofactors in breast cancer cells.
30 Mar 2008
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.